Stemade Biotech

stemade.com

Stemade Biotech Pvt. Ltd. Is the pioneer in the path-breaking concept of dental stem cells preservation in India, and is proud to be India’s first private dental stem cell bank. It provides an excellent opportunity for parents across India to safeguard their child’s health via flexible and affordable pricing plans. The collected dental stem cells can be potentially used to repair and cure 'tissue & organ related diseases' such as bone, cartilage, liver, diabetes, arthritis and many more. Stemade has pioneered this novel concept in India and Asia, having operations in more than 27 locations in India. Stemade aims to be present in at least 50 Indian cities within the first 2 quarters of this financial year. The company was established in year 2009 and launched commercial operations in November 2010. The company is spearheaded by Mr. Deepak Ghaisas, one of the pioneers of the IT revolution in India and has been Vice Chairman, Oracle Financial Services and CEO, iFlex India. Mr. Ghaisas is the first Indian CFO to win the prestigious CFO Asia Award.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

FRONTAGE LABORATORIES ACQUIRES ACCELERA S.R.L.'S BIOANALYTICAL AND DMPK BUSINESSES

Frontage | January 02, 2024

news image

Frontage Laboratories, Inc. announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera). Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery &...

Read More

Medical

VIBE BIO ANNOUNCED THE LAUNCH TO DEVELOP NOVEL TREATMENTS FOR RARE DISEASES

Vibe Bio | June 23, 2022

news image

Vibe Biotechnology Inc., a biotechnology company committed to identifying, funding, and developing promising treatments for rare diseases, announced officially launching with $12 million in funding to advance its community-driven approach to transforming drug development for patients with rare diseases. Vibe Bio plans on building a global community of scientists, researchers, patients, and partners with an aim to find cures for rare diseases by efficiently using a decentralized au...

Read More

Medical, Diagnostics

PREMIER RESEARCH AND INSILICOTRIALS PARTNER FOR RARE DISEASE THERAPY DEVELOPMENT

Premier Research | March 14, 2023

news image

Premier Research has partnered with InSilicoTrials, a leader in using artificial intelligence (AI) and computational modeling and simulation (CM&S) to speed up the development of new therapies and medical devices. Premier Research helps biotech and device companies take their ideas from the idea stage to the commercialization stage. The aim of the partnership is to make it easier, faster, and safer for treatments for rare diseases to get approval from the government. CM&...

Read More

Cell and Gene Therapy

VADERIS THERAPEUTICS AG EMERGES FROM STEALTH AND ANNOUNCES INITIATION OF CLINICAL PROOF-OF-CONCEPT TRIAL IN HHT

Vaderis Therapeutics AG | August 22, 2022

news image

Vaderis Therapeutics AG a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announced its emergence from stealth and initiation of its INSIGHT proof-of-concept clinical trial in patients suffering from Hereditary Haemorrhagic Telangiectasia also known as Osler-Weber-Rendu Syndrome. Vaderis was established in 2019 and in 2020 raised over CHF18 million from Medicxi, enabling progression of its lead asset into the c...

Read More
news image

Medical

FRONTAGE LABORATORIES ACQUIRES ACCELERA S.R.L.'S BIOANALYTICAL AND DMPK BUSINESSES

Frontage | January 02, 2024

Frontage Laboratories, Inc. announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera). Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery &...

Read More
news image

Medical

VIBE BIO ANNOUNCED THE LAUNCH TO DEVELOP NOVEL TREATMENTS FOR RARE DISEASES

Vibe Bio | June 23, 2022

Vibe Biotechnology Inc., a biotechnology company committed to identifying, funding, and developing promising treatments for rare diseases, announced officially launching with $12 million in funding to advance its community-driven approach to transforming drug development for patients with rare diseases. Vibe Bio plans on building a global community of scientists, researchers, patients, and partners with an aim to find cures for rare diseases by efficiently using a decentralized au...

Read More
news image

Medical, Diagnostics

PREMIER RESEARCH AND INSILICOTRIALS PARTNER FOR RARE DISEASE THERAPY DEVELOPMENT

Premier Research | March 14, 2023

Premier Research has partnered with InSilicoTrials, a leader in using artificial intelligence (AI) and computational modeling and simulation (CM&S) to speed up the development of new therapies and medical devices. Premier Research helps biotech and device companies take their ideas from the idea stage to the commercialization stage. The aim of the partnership is to make it easier, faster, and safer for treatments for rare diseases to get approval from the government. CM&...

Read More
news image

Cell and Gene Therapy

VADERIS THERAPEUTICS AG EMERGES FROM STEALTH AND ANNOUNCES INITIATION OF CLINICAL PROOF-OF-CONCEPT TRIAL IN HHT

Vaderis Therapeutics AG | August 22, 2022

Vaderis Therapeutics AG a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announced its emergence from stealth and initiation of its INSIGHT proof-of-concept clinical trial in patients suffering from Hereditary Haemorrhagic Telangiectasia also known as Osler-Weber-Rendu Syndrome. Vaderis was established in 2019 and in 2020 raised over CHF18 million from Medicxi, enabling progression of its lead asset into the c...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us